KARLUS ARTIS: Open Payments
NPI 1649386632 · GOLDSBORO, NC. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,333 in 113 payments from 11 companies in 2025. Trend: 2023 $735 · 2024 $1,133 · 2025 $2,333
Food & beverage: $2,102Education: $231
| Company | Payments | Amount |
|---|---|---|
| E.R. Squibb & Sons, L.L.C. | 16 | $440 |
| Teva Pharmaceuticals USA, Inc. | 11 | $391 |
| Alkermes, Inc. | 18 | $349 |
| Vanda Pharmaceuticals Inc. | 16 | $272 |
| Otsuka America Pharmaceutical, Inc. | 18 | $228 |
| ABBVIE INC. | 17 | $222 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 7 | $174 |
| Axsome Therapeutics, Inc. | 6 | $171 |
| Janssen Pharmaceuticals, Inc | 2 | $45 |
| Tris Pharma Inc | 1 | $22 |
Products named: COBENFY, ARISTADA, HETLIOZ, VRAYLAR, REXULTI, CAPLYTA, Auvelity, UZEDY.
Industry payments across NC — which companies pay providers there.
